Immune checkpoint inhibitors continue to revolutionize the treatment of a wide range of solid-tumor and hematological malignancies, with a growing list of approvals and label expansions. The Immune Checkpoint Inhibitors Special Topics report provides a comprehensive, multi-indication coverage of currently available immune checkpoint inhibitors — ipilimumab (Bristol Myers-Squibb’s Yervoy), nivolumab (Bristol Myers-Squibb’s Opdivo), pembrolizumab (Merck & Co.’s Keytruda), atezolizumab (Roche/Genentech’s Tecentriq), avelumab (Pfizer/Merck KGaA’s Bavencio), and durvalumab (AstraZeneca’s Imfinzi) — and examines their ongoing clinical development across oncology. In addition, analysis of late-phase emerging therapies and their future positioning is provided, along with an annualized top-down market forecast. The report also offers an extensive list of agents in early-phase development, as well as an analysis of the most promising novel targets and combination therapies for immune checkpoint inhibitors.
- What is the landscape for current immune checkpoint inhibitors in oncology? What are the trends in their ongoing clinical development?
- What are the key trends for emerging immune checkpoint inhibitors in late-phase development? How do interviewed experts perceive these therapies?
- What is the market outlook for current and emerging immune checkpoint inhibitors across oncology?
- What are the therapies and/or mechanisms of action to watch in the early-phase pipeline?
- What is the potential of combinatorial approaches involving immune checkpoint inhibitors?